Related Experiment Video
Updated: Jun 28, 2026
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Primary cancer of the sphenoid sinus--a GETTEC study
Pierre Olivier Vedrine1, Juliette Thariat, Olivier Merrot
1Department of Otolaryngology-Head and Neck Surgery, University Hospital, Nancy, France.
Head & Neck
|October 31, 2008
Summary
Primary sphenoid sinus cancers are rare and have a poor prognosis. Early diagnosis and aggressive multidisciplinary management, including surgery, radiotherapy, and chemotherapy, are crucial for improving patient outcomes.
Area of Science:
- Otolaryngology
- Oncology
- Radiology
Background:
- Primary sphenoid sinus tumors are rare, accounting for 2% of paranasal sinus malignancies.
- These tumors are associated with a poor prognosis, and optimal management strategies are still under investigation.
Purpose of the Study:
- To identify prognostic factors for locoregional control and survival in patients with primary sphenoid sinus cancer.
- To evaluate the effectiveness of different treatment modalities, including surgery, radiotherapy, and chemotherapy.
Main Methods:
- Retrospective review of 23 patients treated for primary sphenoid sinus cancer between 1988 and 2004.
- Univariate and multivariate analyses were performed to assess patient-, tumor-, and treatment-related parameters.
Main Results:
- Cranial neuropathies were observed in 12 patients and were associated with worse outcomes.
- Advanced stages (III-IV) were common at presentation. Surgery, when achievable with negative margins, showed better outcomes than non-surgical treatments in non-lymphoma cases.
- Median locoregional control and overall survival were 12 and 41 months, respectively.
Conclusions:
- Early imaging (CT/MRI) is recommended for nonspecific, rhinological, or neuro-ophthalmological symptoms.
- Cranial neuropathies are indicators of a worse prognosis.
- Multidisciplinary management, including surgery, radiotherapy, and chemotherapy, adapted to histology and tumor extent, is essential for improving outcomes in these rare cancers.
